Lorrin Yee

Suggest Changes
Learn More
BACKGROUND AND OBJECTIVE Bortezomib, an antineoplastic for the treatment of relapsed multiple myeloma and mantle cell lymphoma, undergoes metabolism through oxidative deboronation by cytochrome P450(More)
4129 Background: Preclinical data suggest that recombinant human Apo2 ligand/TNF-related apoptosis-inducing ligand (rhApo2L/TRAIL) induces tumor cell death through pro-apoptotic receptors DR4 and(More)
8063 Background: Both ASH/ASCO and NCCN evidence-based guidelines for the treatment of ctx-induced anemia (CIA) recommend achievement and maintenance of hemoglobin (Hb) near 12 g/dL to assure optimal(More)
Chemotherapy-induced anemia (CIA) is responsive to treatment with erythropoiesis-stimulating agents (ESAs) such as darbepoetin alfa. Administration of ESAs on a synchronous schedule with chemotherapy(More)